Pharmaceutical

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in…

5 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

5 months ago

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing…

5 months ago

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced…

5 months ago

Conduit to Change Name to CDT Equity Inc.

Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets…

5 months ago

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product PortfolioTransaction Expands SERB’s Investment in the U.S.SERB to Commence…

5 months ago

Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)…

5 months ago

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug.…

5 months ago

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance…

5 months ago

CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement…

5 months ago